Changes in Plasma Vascular Endothelial Growth Factor at 8 Weeks After Sorafenib Administration as Predictors of Survival for Advanced Hepatocellular Carcinoma

Kaoru Tsuchiya, MD, PhD1; Yasuhiro Asahina, MD, PhD2,3; Shuya Matsuda, MD1; Masaru Muraoka, MD1; Toru Nakata, MD1; Yuichiro Suzuki, MD1; Nobuharu Tamaki, MD1; Yutaka Yasui, MD1; Shoko Suzuki, MD1; Takanori Hosokawa, MD1; Takashi Nishimura, MD, PhD1; Ken Ueda, MD1; Teiji Kuzuya, MD, PhD1; Hiroyuki Nakanishi, MD, PhD1; Jun Itakura, MD, PhD1; Yuka Takahashi, MD, PhD1; Masayuki Kurosaki, MD, PhD1; Nobuyuki Enomoto, MD, PhD4; and Namiki Izumi, MD, PhD1

BACKGROUND: A new predictive biomarker for determining prognosis in patients with hepatocellular carcinoma (HCC) who receive sorafenib is required, because achieving a reduction in tumor size with sorafenib is rare, even in patients who have a favorable prognosis. Vascular endothelial growth factor (VEGF) receptor is a sorafenib target. In the current study, the authors examined changes in plasma VEGF concentrations during sorafenib treatment and determined the clinical significance of VEGF as a prognostic indicator in patients with HCC. METHODS: Plasma VEGF concentrations were serially measured in 63 patients with advanced HCC before and during sorafenib treatment. A plasma VEGF concentration that decreased >5% from the pretreatment level at 8 weeks was defined as a “VEGF decrease.” An objective tumor response was determined using modified Response Evaluation Criteria in Solid Tumors 1 month after the initiation of therapy and every 3 months thereafter. RESULTS: Patients who had a VEGF decrease at week 8 (n = 14) had a longer median survival than those who did not have a VEGF decrease (n = 49; 30.9 months vs 14.4 months; P = .038). All patients who had a VEGF decrease survived for >6 months, and the patients who had both a VEGF decrease and an α-fetoprotein response (n = 6) survived during the observation period (median, 19.7 months; range, 6.5-31.0 months). In univariate analyses, a VEGF decrease, radiologic findings classified as progressive disease, and major vascular invasion were associated significantly with 1-year survival; and, in multivariate analysis, a VEGF decrease was identified as an independent factor associated significantly with survival. CONCLUSIONS: A plasma VEGF concentration decrease at 8 weeks after starting sorafenib treatment may predict favorable overall survival in patients with advanced HCC.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver (70%-85%) and a major cause of mortality. It is the fifth and seventh most frequent cancer and the second and sixth most frequent cause of cancer death in men and women, respectively.1 At early stages or at Barcelona Clinic Liver Cancer stage A, a 5-year survival rate of 60% to 70% can be achieved in well selected patients with HCC who undergo surgical therapies (liver resection or transplantation) or locoregional procedures (ie, radiofrequency ablation).2 However, treatment of advanced HCC that is not amenable to surgical or locoregional therapies remains a challenge in clinical practice.

Sorafenib is an oral, small-molecule tyrosine kinase inhibitor that blocks the synthesis of several intracellular proteins considered to be important for tumor progression, including the platelet-derived growth factor receptor beta, raf kinase, and the vascular endothelial growth factor (VEGF) receptor. VEGF is a homodimeric glycoprotein with a molecular weight of 45 kDa. The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, and a structurally related molecule: placental growth factor. Three high-affinity VEGF tyrosine kinase receptors (VEGFRs) have been identified:

Cancer January 15, 2014 229
administration of sorafenib, suggesting that a change in was observed at 24 hours, 72 hours, and 120 hours after the of sorafenib and the prognosis of patients is necessary. biomarker that can complementarily predict the efficacy concentrations. Therefore, the identification of a new Randomized Protocol (SHARP) trial had normal AFP with advanced HCC in the Sorafenib HCC Assessment phase 3, placebo-controlled, randomized trials, sorafenib treatment significantly improved the time to tumor progression (TTP) and overall survival (OS) of patients with advanced HCC. In those trials, however, no statistically significant pretreatment factors that predicted responses after patients started receiving sorafenib were identified. Therefore, in clinical practice, it is extremely important to identify a predictive post-treatment biomarker that is associated with the treatment efficacy of sorafenib and the prognosis of patients after they start receiving sorafenib.

In general, the efficacy of treating solid tumors with systemic chemotherapy agents is assessed by radiologic findings. In 2010, Lencioni and Llovet published a modification of the Response Evaluation Criteria in Solid Tumors (RECIST). However, the modified RECIST can be used only for typical HCC. Advanced HCCs often have atypical vascular patterns; therefore, evaluating tumor response to sorafenib is difficult with radiologic findings alone. Alternatively, -fetoprotein (AFP) is the most popular tumor marker for HCC, and it has been reported that early AFP responses are a useful surrogate marker for predicting treatment response and prognosis in patients with advanced HCC who receive cytotoxic and antiangiogenic agents. However, approximately 30% of patients with advanced HCC in the Sorafenib HCC Assessment Randomized Protocol (SHARP) trial had normal AFP concentrations. Therefore, the identification of a new biomarker that can complementarily predict the efficacy of sorafenib and the prognosis of patients is necessary.

In a mouse model, an increase in hepatic VEGF levels was observed at 24 hours, 72 hours, and 120 hours after the administration of sorafenib, suggesting that a change in VEGF levels may also occur during sorafenib therapy in humans. Therefore, we evaluated plasma VEGF changes during sorafenib treatment in patients with advanced HCC to determine whether VEGF has potential as a new biomarker for the prediction of treatment efficacy and prognosis after sorafenib administration.

MATERIALS AND METHODS

Patient Selection

Between December 2009 and August 2012, 95 consecutive patients with advanced, inoperable HCC received treatment with sorafenib at Musashino Red Cross Hospital. The diagnosis of HCC was based on guidelines established by the Liver Cancer Study Group of Japan and the American Association for the Study of Liver Diseases or by pathologic examination. According to these guidelines, a diagnosis of HCC is confirmed by histology or by characteristic radiologic findings, such as typical arterial enhancement of the tumor followed by a washout pattern in the images in the portal venous phase or the equilibrium phase on dynamic spiral computed tomography (CT) imaging or contrast-enhanced magnetic resonance imaging. Inclusion criteria were predefined as follows: 1) patients were alive 8 weeks after beginning treatment; and 2) patients had plasma VEGF and serum AFP concentrations evaluated at baseline, at 4 weeks, and at 8 weeks. Of 95 patients, 23 were unavailable for a week-8 VEGF measurement for the following reasons: 7 patients stopped sorafenib therapy because of erythema multiforme (grade 2-3) and started other therapies (radiation therapy or cytotoxic chemotherapy) within 1 month after starting sorafenib, 4 patients moved to another location before week 8, 5 patients refused to undergo a plasma VEGF measurement at week 8, and 7 patients were not available for obtaining VEGF concentration results. These 23 patients and 9 other patients who died within 8 weeks were excluded from the study. Hence, in total, 63 patients fulfilled the inclusion criteria. At enrollment, all patients had metastatic or locally advanced HCC that was not amenable to surgery or locoregional therapies, including transcatheter arterial chemoembolization (TACE) and local ablation. Written informed consent was obtained from all patients, and the ethics committee at Musashino Red Cross Hospital approved the study in accordance with the Declaration of Helsinki.

Sorafenib Treatment

The initial daily dose of sorafenib was 800 mg in 28 patients, 400 mg in 28 patients, and 200 mg in 7 patients. A reduced initial dose was allowed for patients who had the following factors: advanced age (≥80 years), gastrointestinal varices with a risk of bleeding, low body weight (<50 kg), and a poor performance status (≥2). In total, 60 patients underwent multiphase-multidetector CT imaging before starting sorafenib, 1 month after starting sorafenib, and every 3 months thereafter. Radiologic responses to therapy were evaluated according to modified RECIST. In all patients, serial measurements of plasma VEGF and serum AFP concentrations were performed before and after the receipt sorafenib and every month thereafter, with an allowance of ± 1 week. The endpoint of the current study was OS. In the follow-up visit after sorafenib administration, the medication was discontinued if progressive disease
(PD) was identified despite treatment, if intolerable adverse events occurred, or if inappropriate liver function was observed. Other palliative treatments or best supportive care were provided subsequently. An AFP response was defined as a decrease ≥20% in the serum AFP concentration during 8 weeks of treatment.

**Plasma VEGF Measurements**

Serial serum samples were collected prospectively from each patient. Venous blood samples were drawn into a serum separator tube and centrifuged at \( \times 1800g \) for 10 minutes, and plasma samples were stored at \(-80^\circ C\) until measurement. Plasma VEGF concentrations were measured quantitatively using an enzyme-linked immunosorbent assay kit (Quantikine Human VEGF Immunoassay; R&D Systems, Minneapolis, Minn) according to the manufacturer’s instructions. We defined a decrease in the plasma VEGF level >5% from the pretreatment level at 8 weeks as a “VEGF decrease.”

**Statistical Analysis**

Categorical variables were compared using the chi-square test, and continuous variables were compared using the Mann-Whitney test. All tests of significance were 2-tailed, and \( P \) values \(< .05\) were considered statistically significant. OS curves were calculated using the Kaplan-Meier method, and differences between groups were assessed using the log-rank test. OS was determined as the interval between the date of treatment initiation and either death or the last visit. A Cox proportional-hazards model was used to determine the factors associated with OS. In univariate analyses, clinical and biologic parameters (sex, age, etiology, albumin, bilirubin concentrations, Child-Pugh class, plasma VEGF concentrations, and serum AFP concentrations) and tumor factors (vascular invasion and distant metastasis) were included. A logistic regression model was used to identify the factors associated with 1-year survival after the receipt of sorafenib. All statistical analyses were performed using StatView (version 5.0) software (Abacus Concepts, Berkeley, Calif).

**RESULTS**

**Patient Characteristics**

In total, 63 patients were enrolled in this study, and their characteristics are listed in Table 1. The diagnosis of HCC was confirmed by histology in 11 patients and by typical radiologic findings based on established guidelines in the remaining 52 patients. In all, 51 patients had previously received other therapeutic modalities, including 22 patients who previously received radiofrequency ablation, 22 who previously underwent TACE, 1 who previously received transcatheter arterial chemoinfusion, and 6 who previously underwent hepatic resection. Twelve patients had received sorafenib as initial therapy for HCC. Among the 63 enrolled patients, 33 were seropositive for hepatitis C virus antibody, 8 were seropositive for hepatitis B surface antigen, and 22 were seronegative for both hepatitis C virus antibody and hepatitis B surface antigen. Eighteen patients had evidence of extrahepatic metastasis, and 18 had major vascular invasion. No patient was lost to follow-up in this study.

**Pretreatment Plasma VEGF Concentration and Prognosis and Extent of Hepatocellular Carcinoma**

Pretreatment plasma VEGF concentrations in the 9 patients who died within 8 weeks were significantly higher than in the patients who survived beyond 8 weeks \((813 \pm 630\; \text{pg/mL} \; \text{vs} \; 384 \pm 18\; \text{pg/mL}; \; P = .0024)\). Consistent with a previous study (the SHARP trial; Llovet et al\(^3\)), our data suggested that the pretreatment plasma VEGF concentration is a useful prognostic factor for sorafenib therapy. However, there was no significant difference in OS between patients who had pretreatment plasma VEGF concentrations \(\leq 450\; \text{pg/mL}\) \((n = 46)\) and those who had concentrations \(>450\; \text{pg/mL}\) \((n = 17); \; P = .731\). The pretreatment plasma VEGF concentration could not predict prognosis for the patients who survived beyond 8 weeks.

We compared the size and extent of HCC between patients who had low plasma VEGF concentrations \(\leq 450\; \text{pg/mL}\) and high plasma VEGF concentrations \((>450\; \text{pg/mL})\). No difference was observed in the size or extent of HCC at baseline between patients with lower versus higher pretreatment plasma VEGF concentrations.

**Association Between Changes in Plasma VEGF Concentrations and Overall Survival**

The median OS assessed by the Kaplan-Meier method was 16.3 months for all 63 patients enrolled in the study.
Plasma VEGF concentrations at baseline, at 4 weeks, and at 8 weeks after the initiation of sorafenib treatment were 288 pg/mL (range, 60-1580 pg/mL), 372 pg/mL (range, 69-1990 pg/mL), and 347 pg/mL (range, 64-1840 pg/mL), respectively (Fig. 2). Plasma VEGF concentrations increased within 4 weeks after the administration of sorafenib in 47 of 63 patients (74.6%). The median survival of patients who had a decrease in their plasma VEGF concentration at week 4 (n = 16) and an increase in their plasma VEGF concentration at week 4 (n = 47) were 19.5 months and 16.8 months, respectively; and there was no significant difference in OS between changes in plasma VEGF at 4 weeks (P = .645). However, patients who had a VEGF decrease at week 8 (n = 14) had a longer median survival than those who did not have a VEGF decrease (n = 49; 30.9 months vs 14.4 months; P = .038) (Fig. 3), suggesting that a decrease in VEGF concentration 8 weeks after starting sorafenib treatment is closely associated with a favorable prognosis. The median percentage of decrease in the plasma VEGF concentration was 18.3% (range, 7%-41.7%). There were no differences in any pretreatment patient characteristics, including HCC stage and Child-Pugh score, between patients who did and did not have a VEGF decrease (Table 2).

**Relation Between Radiologic Findings or Serum \(\alpha\)-Fetoprotein Concentration and Overall Survival**

The best radiologic responses to therapy assessed by modified RECIST were classified as a complete response (CR) (n = 4), a partial response (PR) (n = 16), stable disease (SD) (n = 34), and PD (n = 9). Fourteen patients had a VEGF decrease, and their best radiologic responses were a CR (n = 2), a PR (n = 2), SD (n = 9), and PD (n = 1). There was no significant difference in OS between the patients who had an objective response (CR + PR) and those with SD. The survival of patients who had PD was significantly worse than that of the patients without PD (median OS, 5.8 months and 19.4 months, respectively; P = .0006). There was no significant difference in OS between patients who had an AFP response and those who did not have an AFP response within the group that did not have PD (ie, those who attained a CR, a PR, or SD [the non-PD group]) (Fig. 4). There also was no significant difference (P = .111) between patients who did and did not have an AFP response among those in the non-PD group who had had an elevated AFP at baseline.
It is noteworthy that all patients who had a VEGF decrease and an AFP response survived during the observation period (median, 19.7 months; range, 6.5-31.0 months). In patients without a VEGF response \((n = 49)\), there was no significant difference in OS between those who did and did not have an AFP response \((P = .147)\). Of 49 patients who did not have a VEGF decrease at 8 weeks, 19 patients were able to survive beyond 1 year after starting sorafenib. Nine patients without a VEGF decrease at 8 weeks survived for >18 months.

### Prognostic Factors After Sorafenib Administration

In univariate analysis, among all patients, a VEGF decrease and an AFP response were associated significantly with OS after starting sorafenib. Major vascular invasion and PD, as evidenced by radiologic findings after sorafenib administration, also were significant prognostic factors. To predict which patients would have a highly favorable prognosis, the prognostic factors associated with 1-year survival after starting sorafenib were assessed in univariate and multivariate analyses. In the univariate analysis, a VEGF decrease, PD, and major vascular invasion were associated significantly with survival (Table 3). In the multivariate analysis, which was performed using those factors as covariates, a VEGF decrease was identified as an independent factor associated significantly with survival \((P = .0013)\) (Fig. 5). Only 1 patient who had a VEGF decrease was classified with PD. All 4 patients who had a VEGF decrease and an objective response (CR or PR) were able to survive during the observation period.

### Adverse Events During Sorafenib Treatment

The overall incidence of treatment-related adverse events was 100%. The rate of discontinuation of sorafenib as a result of adverse events was 22.2%. Adverse events that led to the discontinuation of sorafenib treatment were liver dysfunction (63.6%), hand-foot skin reaction (18.2%), interstitial pneumonia (9.1%), and rash (9.1%). Dose reductions because of adverse events occurred in 62 patients. The most frequent adverse event leading to dose reductions was liver dysfunction (33.9%). In addition,

### TABLE 2. Characteristics of Patients Categorized According to Variation in Vascular Endothelial Growth Factor Levels at 8 Weeks of Sorafenib Treatment

| Characteristic | With VEGF Decrease, n = 14 | Without VEGF Decrease, n = 49 | \(P\) |
|---------------|---------------------------|-------------------------------|------|
| Age, y        | 72                        | 69                            | .325 |
| Sex: Men      | 11 (78.6)                 | 42 (85.7)                     | .679 |
| Body weight, kg | 58.3                     | 62.3                          | .175 |
| Cause of disease |                          |                               |     |
| Hepatitis B   | 0 (0)                     | 8 (16.3)                      |     |
| Hepatitis C   | 9 (64.3)                  | 24 (49)                       |     |
| Other         | 5 (35.7)                  | 17 (34.7)                     |     |
| Prior treatment |                          |                               | .797|
| Yes           | 11 (78.6)                 | 40 (81.6)                     |     |
| No            | 3 (21.4)                  | 9 (18.4)                      |     |
| Baseline bilirubin, mg/dL | 0.8                     | 1.0                           | .375 |
| Baseline albumin, g/dL     | 3.4                      | 3.6                           | .190 |
| Child-Pugh score |                            |                               | .178|
| 5             | 7 (50)                    | 30 (61.2)                     |     |
| 6             | 7 (50)                    | 16 (32.7)                     |     |
| 7             | 0 (0)                     | 3 (6.1)                       |     |
| Maximum tumor size, cm     |                          |                               | .892|
| ≤5            | 8 (57.1)                  | 22 (44.9)                     |     |
| >5            | 6 (42.9)                  | 27 (55.1)                     |     |
| No. of tumors <3            | 10 (71.4)                | 34 (69.4)                     | .883 |
| >3            | 4 (28.6)                  | 15 (30.6)                     |     |
| Extrahepatic disease |                        |                               | .502|
| Yes           | 3 (21.4)                  | 15 (30.6)                     |     |
| No            | 11 (78.6)                 | 34 (69.4)                     |     |
| Site of metastatic disease |                          |                               |     |
| Lung          | 1                         | 7                             |     |
| Bone          | 1                         | 4                             |     |
| Lymph node    | 1                         | 3                             |     |
| Lung and bone | 0                         | 1                             |     |
| Major vascular invasion |                        |                               | .739|
| Yes           | 3 (21.4)                  | 15 (30.6)                     |     |
| No            | 11 (78.5)                 | 34 (69.4)                     |     |

Abbreviations: VEGF: vascular endothelial growth factor.
the incidence of adverse events was not related to plasma VEGF concentrations.

**DISCUSSION**

In the current study, we demonstrated that plasma VEGF concentrations change dynamically during sorafenib therapy, and changes in VEGF concentration are closely associated with OS in patients who receive treatment with sorafenib. VEGF is the major mediator of angiogenesis in HCC, and several studies have correlated VEGF concentrations with the prognosis of patients who have advanced HCC.

**TABLE 3. Prognostic Factors Associated With 1-Year Survival After Sorafenib Administration**

| Risk Factor                                      | OR (95% CI) | P    |
|--------------------------------------------------|-------------|------|
| **Univariate analysis**                          |             |      |
| Age, by every 10 y                               | 1.47 (0.75-2.87) | .266 |
| Sex                                              |             |      |
| Women                                            | 1.00        |      |
| Men                                              | 0.26 (0.50-1.39) | .116 |
| HBV infection                                    |             |      |
| Negative                                         | 1.00        |      |
| Positive                                         | 0.33 (0.06-2.02) | .231 |
| HCV infection                                    |             |      |
| Negative                                         | 1.00        |      |
| Positive                                         | 1.23 (0.41-3.74) | .714 |
| Albumin, by every 1 g/dL                          | 1.34 (0.45-3.99) | .604 |
| Total bilirubin, by every 1 mg/dL                | 0.79 (0.28-2.25) | .656 |
| Pre-AFP, by every 10 ng/mL                       | 1.00 (1.00-1.00) | .161 |
| Tumor size, cm                                   |             |      |
| <5                                               | 1.00        |      |
| ≥5                                               | 0.42 (0.14-1.32) | .147 |
| No. of tumors                                    |             |      |
| <4                                               | 1.00        |      |
| ≥4                                               | 0.26 (0.06-1.08) | .064 |
| Major vascular invasion                          |             |      |
| Yes                                              | 1.00        |      |
| No                                               | 4.00 (1.12-14.4) | .034 |
| Extrahepatic metastasis                          |             |      |
| Yes                                              | 1.82 (0.56-5.90) | .320 |
| No                                               | 1.00        |      |
| 5% VEGF decrease at wk 8                         |             |      |
| No                                               | 1.00        |      |
| Yes                                              | 11.1 (1.29-94.6) | .028 |
| PD                                               |             |      |
| No                                               | 1.00        |      |
| Yes                                              | 0.16 (0.29-0.86) | .033 |
| Objective response: CR + PR                       |             |      |
| No                                               | 1.00        |      |
| Yes                                              | 1.63 (0.49-5.42) | .426 |
| AFP response                                     |             |      |
| No                                               | 2.76 (0.80-9.52) | .107 |
| Yes                                              | 1.00        |      |
| Multivariate analysisb                           |             |      |
| 5% VEGF decrease at wk 8                         |             |      |
| No                                               | 1.00        |      |
| Yes                                              | 10.0 (1.02-91.3) | .041 |
| PD                                               |             |      |
| No                                               | 1.00        |      |
| Yes                                              | 0.20 (0.29-1.39) | .104 |
| Major vascular invasion                          |             |      |
| Yes                                              | 1.00        |      |
| No                                               | 3.03 (0.71-12.9) | .134 |

Abbreviations: AFP, α-fetoprotein; CI, confidence interval; CR, complete response; HBV, hepatitis B virus; HCV, hepatitis C virus; PD, progressive disease; PR, partial response; VEGF, vascular endothelial growth factor.

The ORs for 1-year survival were calculated using logistic regression analysis.

In the multivariate logistic analysis, a 5% VEGF decrease, PD, and portal invasion were included as covariates.

Recently, a new staging system was proposed that includes the plasma VEGF concentration along with the Cancer of the Liver Italian Program (CLIP) score; this new system—known as the V-CLIP score—classifies patients with advanced HCC more appropriately into a homogeneous prognostic group. Therefore, the concentration of circulating VEGF is included as a candidate prognostic marker for HCC, especially in patients with advanced disease. The objective of our study was to elucidate the important question of whether an on-treatment change in VEGF is a potentially useful new biomarker for predicting prognosis in patients who survive beyond 8 weeks, because such an on-treatment predictor among patients who have relatively longer survival has not yet been elucidated. In this study, plasma VEGF concentrations increased from pretreatment levels within 4 weeks of starting sorafenib in 47 of 63 patients (74.6%). This was followed by a decrease in plasma VEGF levels at 8 weeks in 68.1% of patients. A possible mechanism of this transient increase in VEGF after starting sorafenib may be related to a reactive increase against the inhibition of VEGF activity or hypoxia induced by sorafenib. This
hypothesis is supported by the demonstration that plasma VEGF concentrations increased shortly after treatment with TACE.²⁴-²⁶ It is believed that these increases in plasma VEGF concentration are related to the induction of tissue hypoxia.²⁷ However, the peak time point of VEGF elevation during sorafenib administration was different from that previously reported in TACE, in which a transient elevation of VEGF was observed within 7 days after TACE.²⁴-²⁶ This observed difference may be related to the continuous induction of hypoxia by sorafenib administration.

It is noteworthy that, in our study, decreases in plasma VEGF observed within 8 weeks of sorafenib administration were associated with better OS. One possible reason for this association may be that the decrease in VEGF concentrations reflects a decrease in the number of tumor cells secreting VEGF. An association between changes in VEGF concentrations and disease progression was observed in a previous study of an anti-VEGF antibody, bevacizumab, in patients with advanced HCC.²³ In that study, plasma VEGF-A concentrations decreased from baseline in all patients after 8 weeks of bevacizumab therapy and increased to near baseline levels in 5 of 6 patients at the time of disease progression. Unfortunately, plasma VEGF-A levels after 8 weeks of bevacizumab in that study were available for only 8 of 46 patients who were enrolled in the study, and plasma VEGF-A levels after 4 weeks were not evaluated. In our study, all patients were evaluated before and every 4 weeks after starting sorafenib. Moreover, we demonstrated the usefulness of plasma VEGF concentrations at 8 weeks and not at 4 weeks. Zhu et al²⁸ reported that plasma levels of VEGF and placental growth factor increased after cediranib, a pan-VEGFR tyrosine kinase inhibitor monotherapy for advanced HCC. In that study, progression-free survival was correlated inversely with baseline levels of VEGF, soluble VEGFR2 (sVEGFR2), and basic fibroblast growth factor and with on-treatment levels of basic fibroblast growth factor and insulin-like growth factor-1; and progression-free survival was directly associated with on-treatment levels of interferon-γ. Because changes of VEGF concentrations during therapy were not identified as a prognostic factor in the study by Zhu et al, biomarkers that predict prognosis may be different among different types of tyrosine kinase inhibitors. Jayson et al²⁹ reported that plasma VEGF-A in patients who received bevacizumab was potentially predictive and prognostic in metastatic breast, gastric, and pancreatic cancers; however, it was only prognostic (and not predictive) in metastatic colorectal cancer, nonsmall cell lung cancer, and renal cell carcinoma. In our study, we measured plasma VEGF concentrations and not plasma VEGF-A concentrations. Sorafenib is a multitargeted inhibitor, whereas bevacizumab is a humanized monoclonal antibody that recognizes and blocks VEGF-A expression. Further studies to evaluate the clinical usefulness of determining VEGF and VEGF-A concentrations during sorafenib therapy are necessary in various cancers. Although the precise mechanism underlying the association between serial changes in VEGF and disease progression is unclear, the findings of the current study are extremely valuable for clinical practice in predicting the prognosis of patients who receive treatment with sorafenib.

Llovet et al⁵ studied plasma biomarkers as predictors of outcome in patients with advanced HCC. They measured plasma biomarkers in 491 patients at baseline and in 305 patients after 12 weeks in a phase 3, randomized, controlled trial (the SHARP trial). Those authors concluded that angiopoietin-2 and VEGF were independent predictors of survival in patients with advanced HCC and that none of the tested biomarkers significantly predicted response to sorafenib. In our study, by measuring plasma VEGF monthly, we demonstrated that the changes 8 weeks after starting sorafenib were important for predicting OS.

It has been reported that modified RECIST guidelines are useful for predicting efficacy and prognosis after patients with advanced HCC receive treatment with sorafenib.³⁰ However, modified RECIST can only be used for typical hypervascular HCC, and not for atypical HCC, including poorly differentiated HCC and diffuse-type HCC. Moreover, the percentage of patients in our study who had PD was only 11.1% (9 of 63 patients), and the objective response rate (CR + PR vs SD) could not predict OS, suggesting that using only modified RECIST guidelines was insufficient for predicting OS in most patients who received sorafenib (non-PD patients). Therefore, it is important to identify a predictive biomarker for those patients who can expect long survival during sorafenib therapy, although their radiologic findings may not be categorized as objective responses.

From this point of view, decreases in VEGF observed in non-PD patients at week 8 may identify patients who have a favorable prognosis. According to our results, the median survival of patients who had a VEGF decrease was extremely good at 31.0 months, and we demonstrated that a VEGF decrease, but not modified RECIST or AFP, was the only significant post-therapeutic factor associated with favorable survival after sorafenib administration (Table 3). In our study, all
patients who had both a VEGF decrease and an AFP response survived during the observation period (median, 19.7 months). Taken together, the combination of a plasma VEGF decrease, an AFP response, and modified RECIST is useful for predicting an extremely favorable prognosis.

This study had a few limitations. The first was our subanalysis of consecutive patients. However, the median survival for the 23 excluded patients who were available for estimation was equivalent to that of the included patients (16.8 months); therefore, it is unlikely that selection bias affected our results. The second limitation is that we measured only plasma VEGF concentrations. In previous studies, many factors, including VEGF-A, short VEGF-A isoform, sVEGFR1, sVEGFR2, sVEGFR3, angiopoietin-2, and insulin-like growth factor-2, were evaluated as biomarkers. However, to our knowledge, this is the first clinical study to demonstrate the early dynamic changes in plasma VEGF concentrations in patients who received sorafenib. Finally, the number of patients in this study was relatively small to make recommendations to physicians. Our results indicated that patients who have decreased VEGF concentrations at 8 weeks have a favorable prognosis, regardless of their radiologic findings. However, further studies with a larger number of patients will be necessary to propose new recommendations.

In conclusion, changes in plasma VEGF concentrations during sorafenib treatment are dynamic in patients with advanced HCC, and an observed decrease in the plasma VEGF concentration 8 weeks after starting sorafenib is associated significantly with favorable OS. Today, because many clinical trials of new molecular-targeted agents for HCC are being conducted, it is necessary for hepatologists and oncologists to determine the time when alternative agents should be started as a second or third line of treatment. Our results have potentially important clinical implications for physicians and may influence their decisions regarding a treatment strategy for advanced HCC in individual patients.

**FUNDING SUPPORT**

This work was supported by grants from the Japanese Ministry of Welfare, Health, and Labor.

**CONFLICT OF INTEREST DISCLOSURES**

Yasuhiro Asahina received grants from the Japanese Ministry of Welfare, Health, and Labor and the Japanese Ministry of Education, Culture, Sports, and Science during the conduct of this study. Dr. Asahina has also received grants from Chugai Pharmaceutical Company, Ltd.; Toray Industries, Inc.; Bristol-Myers Squibb; Dai-nippon Sumitomo Pharma Company, Ltd.; Merck Sharp & Dohme (MSD); and Daiichi Sankyo Company, Ltd., and has received lecture fees from Chugai Pharmaceutical Company, Ltd. and MSD. Nobuyuki Enomoto has received grants and consulting fees from Bayer, Chugai-Roche, MDS, Bristol-Myers Squibb, and GlaxoSmithKline. Namiki Izumi has received lecture fees from MSD, Chugai Pharmaceutical Company, Ltd.; Daiichi-Sankyo Company, Ltd.; Bayer AG; and Bristol-Myers Squibb.

**REFERENCES**

1. World Health Organization, International Agency for Research on Cancer (IARC); Boyle P, Levin B, eds. World Cancer Report 2008. Lyon, France: IARC Press 2008.
2. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.
3. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
4. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
5. Llovet JM, Penu CE, Lathia CD, Shan M, Meinhardt G, Bruix J. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18:2290-3000.
6. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
7. Shao YY, Lin ZZ, Hsu C, Shen CH, Cheng AL. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010;116:4590-4596.
8. Kuzuya T, Asahina Y, Tsujiyuki K, et al. Early decrease in alpha-fetoprotein, but not des-y-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology. 2011;81:251-258.
9. Personeni N, Bozzarelli S, Pressiani T, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012;57:101-107.
10. Raoul JL, Bruix J, Greten TF, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol. 2012;56:1080-1088.
11. Hora C, Romanque P, Dufour JF. Effect of sorafenib on murine liver regeneration. Hepatology. 2011;53:577-586.
12. Kudo M, Izumi N, Kokudo N, Matsuoi O, Sakamoto M, Makuchii M. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29:339-364.
13. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
14. El-Assal ON, Yamanoi A, Suda Y, et al. Clinical significance of microvesSEL density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology. 1998;27:1554-1562.
15. Yamaguchi R, Yano H, Iemura A, Ogawa S, Hiramaki M, Kojiri M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 1998;28:68-77.
16. Yoshiji H, Kuriyama S, Yoshii J, et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology. 2002;35:834-842.
17. Tamesa T, Inuzuka N, Mori N, et al. High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma. Hepatogastroenterology. 2009;56:1122-1126.
18. Hu J, Xu Y, Shenn ZZ, et al. High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor

Cancer January 15, 2014
predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. *J Cancer Res*. 2009;135:1359-1367.

19. Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. *Ann Surg Oncol*. 2007;14:1835-1845.

20. Schoenleber SJ, Kurtz DM, Tabwalkar JA, Rober LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: a review of literature. *Br J Cancer*. 2009;100:1385-1392.

21. Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma: phase II study. *Clin Cancer Res*. 2013;19:1557-1566.

22. Kaseb AO, Hassan M, Lin E, Xiao L, Kumar V, Morris J. V-CLIP: integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. *Cancer*. 2011;117:2478-2488.

23. Siegel AB, Cohen EL, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. *J Clin Oncol*. 2008;26:2992-2998.

24. Liu X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. *World J Gastroenterol*. 2004;10:2878-2882.

25. Suzuki H, Mori M, Kawaguchi C, Adachi M, Miura S, Ishii H. Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma. *Int J Oncol*. 1999;14:1087-1090.

26. Shim JH, Park JW, Kim JH, et al. Association between increment of serum VEGF and poor prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. *Cancer Sci*. 2008;99:2037-2044.

27. von Marschall Z, Cramer T, Hocker M, Finkenzeller G, Wiedenmann B, Rosewicz S. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. *Gut*. 2001;48:87-96.

28. Zhu AX, Ancukiewicz M, Duda DG, et al. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. *Clin Cancer Res*. 2013;19:1557-1566.

29. Jayson GC, de Haas S, Delmar P, et al. Evaluation of plasma VEGF-A as a potential predictive pan-tumour biomarker for bevacizumab. Abstract 804. Paper presented at: 2011 European Multidisciplinary Cancer Congress; Stockholm, Sweden; September 23-27, 2011.

30. Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. *Cancer*. 2012;118:147-156.